Use of functional analysis methodology in the evaluation of medication effects.

Two children with autism took part. Each had severe destructive behavior.

The team ran a full functional analysis before starting any pills. They tested if the behavior was kept going by escape, adult attention, or access to toys.

After the FA, each child began risperidone. The researchers kept watching behavior under the same test conditions.

Risperidone helped only when the behavior was driven by escape. Rates dropped in the escape condition and stayed low.

Behaviors that worked to get toys or adult attention barely changed. The pill left those patterns untouched.

Medication effects are function-specific. You have to know the function before you can predict what will improve.

Matson et al. (2011) pooled six large trials and saw risperidone beat placebo for overall problem behavior. Our case-level view says that win hides a detail: only escape-maintained behavior actually falls.

Mace et al. (2009) ran a similar FA-plus-med design with stimulants. They also found drug effects shift with the motivating operation, backing the idea that function matters for any medication.

Boyle et al. (2024) remind us that most real-life behavior is multiply controlled. Their review urges separate FA conditions, exactly what A et al. did, so you can see which pieces respond to drug and which need behavior work.

Pickering et al. (1985) already showed contingency management beating older drugs. The new twist here is using FA data to decide when a modern antipsychotic is worth adding.

If you support a child starting risperidone, run or request an FA first. Share the escape, attention, and tangible results with the prescriber. When escape is the big driver, the drug has a fair shot. If attention or tangibles run the show, push for a behavior plan first and save the family side effects, cost, and false hope.